129 related articles for article (PubMed ID: 36065151)
1. Role of β1-integrin in promoting cell motility and tamoxifen resistance of human breast cancer MCF-7 cells.
Hu S; Yang Q; Chen Z; Fu W
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e223-e230. PubMed ID: 36065151
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.
Zhou C; Zhong Q; Rhodes LV; Townley I; Bratton MR; Zhang Q; Martin EC; Elliott S; Collins-Burow BM; Burow ME; Wang G
Breast Cancer Res; 2012 Mar; 14(2):R45. PubMed ID: 22417809
[TBL] [Abstract][Full Text] [Related]
4. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
5. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
6. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
7. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
[TBL] [Abstract][Full Text] [Related]
8. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
9. Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines.
Zeng Q; Lin X; Chen H; Yan Y; Wang X
Breast Cancer; 2022 May; 29(3):458-467. PubMed ID: 35041152
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
13. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
14. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
15. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
Shi YF; Lu H; Wang HB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
[TBL] [Abstract][Full Text] [Related]
16. Relationship of micro-RNA, mRNA and eIF Expression in Tamoxifen-Adapted MCF-7 Breast Cancer Cells: Impact of miR-1972 on Gene Expression, Proliferation and Migration.
Behringer A; Stoimenovski D; Porsch M; Hoffmann K; Behre G; Grosse I; Kalinski T; Haybaeck J; Nass N
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883472
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
[TBL] [Abstract][Full Text] [Related]
18. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.
Pontiggia O; Sampayo R; Raffo D; Motter A; Xu R; Bissell MJ; Joffé EB; Simian M
Breast Cancer Res Treat; 2012 Jun; 133(2):459-71. PubMed ID: 21935603
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
20. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]